The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial

Journal:
Journal of the National Cancer Institute
Published:
DOI:
10.1093/jnci/djag095
Affiliations:
13
Authors:
15
Go to article
Institutions Authors Share
Institute Jules Bordet, ULB, Belgium
4.500000
 0.30
Frontier Science (Scotland) Ltd (FSS), United Kingdom (UK)
2.000000
 0.13
IRCCS National Cancer Institute (INT) Milan, Italy
1.000000
 0.07
Daiichi Sankyo US, United States of America (USA)
1.000000
 0.07
BMS Switzerland, Switzerland
1.000000
 0.07
The University of Edinburgh, United Kingdom (UK)
1.000000
 0.07
F. Hoffmann-La Roche Ltd., Switzerland
1.000000
 0.07
IRCCS European Institute of Oncology (IEO), Italy
1.000000
 0.07
Sapienza University of Rome, Italy
0.500000
 0.03
University of Genova, Italy
0.500000
 0.03
IRCCS Azienda Ospedaliera Universitaria San Martino, Italy
0.500000
 0.03
Peter MacCallum Cancer Centre (Peter Mac), Australia
0.500000
 0.03
The University of Melbourne (UniMelb), Australia
0.500000
 0.03
Interested in Oncology and Carcinogenesis?